ENLIVEN THERAPEUTICS INC. - COMMON STOCK

27.53

04-October-24 15:59:59

15 minutes delayed

Stocks

+2.02

+7.92%

Today's range

25.48 - 27.62

ISIN

N/A

Source

NASDAQ

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

28 Sep 2024 09:35:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

18 Sep 2024 16:05:07 By Nasdaq GlobeNewswire
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

13 Aug 2024 16:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics to Present at Two Upcoming Investor Conferences

29 May 2024 16:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

14 May 2024 16:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

11 Apr 2024 07:55:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

09 Apr 2024 16:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.